Patents Represented by Attorney, Agent or Law Firm Steven M. Odre
  • Mutants of the green fluorescent protein having improved fluorescent properties at 37.degree.
    Patent number: 6096865
    Abstract: The present invention relates to mutants of the green fluorescent protein having improved fluorescent properties at 37.degree. C. The mutants provide for improved methods of monitoring gene expression, e.g., for use as cell markers or protein expression indicators in prokaryotic and, especially, eucaryotic systems where the standard physiological temperature is 37.degree. C.
    Type: Grant
    Filed: May 6, 1996
    Date of Patent: August 1, 2000
    Assignee: Amgen Inc.
    Inventor: Mark Michaels
  • Glial cell line-derived neurotrophic factor
    Patent number: 6093802
    Abstract: A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: July 25, 2000
    Assignee: Amgen Inc.
    Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
  • Eck receptor ligands
    Patent number: 6087167
    Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: July 11, 2000
    Assignee: Amgen Inc.
    Inventors: Timothy D. Bartley, William J. Boyle, Gary M. Fox, Andrew A. Welcher, Ella Magal, Richard A. Lindberg, Vann P. Parker
  • Mice lacking expression of osteoprotegerin
    Patent number: 6087555
    Abstract: Disclosed is a mouse in which expression of the gene encoding Osteoprotegerin is suppressed. Also disclosed is a nucleic acid construct useful in preparing such a mouse, and a cell line containing such construct.
    Type: Grant
    Filed: October 15, 1997
    Date of Patent: July 11, 2000
    Assignee: Amgen Inc.
    Inventors: Colin Dunstan, Scott Simonet, Ildiko Sarosi
  • Monoclonal antibody against utricular epithelium
    Patent number: 6080845
    Abstract: A non-naturally occurring peptide derived from EGF-like domains of NDF/heregulin protein isoforms is used to stimulate the proliferation of cells in the sensory epithelium of the inner ear. A monoclonal antibody against adult rat utricular epithelium is also described.
    Type: Grant
    Filed: January 28, 1999
    Date of Patent: June 27, 2000
    Assignee: Amgen Inc.
    Inventor: Josette F. Carnahan
  • Method for promoting cell proliferation and growth
    Patent number: 6075008
    Abstract: A method is disclosed which provides for the proliferation and growth of cells, such as prostate cells, by contacting them with an effective amount of a placental-derived prostate growth factor.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: June 13, 2000
    Assignee: Amgen Inc.
    Inventors: Catherine L. Farrell, Francis H. Martin, Rachel Yabkowitz
  • Agouti-related proteins
    Patent number: 6060589
    Abstract: Disclosed is a novel gene termed ART which is expressed primarily in selected regions of the brain, as well as adrenal and lung tissues. Polypeptides encoded by ART are also disclosed, as are methods for preparing ART DNA and amino acid sequences.
    Type: Grant
    Filed: March 2, 1998
    Date of Patent: May 9, 2000
    Assignee: Amgen Inc.
    Inventors: Kevin Lee Stark, Roland Luethy
  • Method for preventing and treating hearing loss using a neuturin protein product
    Patent number: 6043221
    Abstract: The present invention relates generally to methods for preventing and/or treating injury or degeneration of cochlear hair cells and spiral ganglion neurons by administering a neurturin neurotrophic factor protein product. The invention relates more specifically to methods for treating sensorineural hearing loss.
    Type: Grant
    Filed: June 29, 1998
    Date of Patent: March 28, 2000
    Assignee: Amgen Inc.
    Inventors: Ella Magal, John M. Delaney
  • Nucleic acids encoding myocardial peptides
    Patent number: 6034230
    Abstract: Disclosed are novel peptides that modulate inflammatory heart disease. Also disclosed are DNA molecules encoding the peptides, and methods of making the peptides.
    Type: Grant
    Filed: May 3, 1999
    Date of Patent: March 7, 2000
    Assignee: Amgen Canada Inc.
    Inventors: Kurt Bachmaier, Andrew John Hessel, Nickolaus Neu, Josef Martin Penninger
  • Diagnostic method for detection of placental-derived prostate growth factors
    Patent number: 6025204
    Abstract: A diagnostic method is described for the detection of placental-derived growth factors which involves contacting a biological tissue or fluid sample with a labeled antibody which is specific to the growth factors and detecting the labeled reaction product.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: February 15, 2000
    Assignee: Amgen Inc.
    Inventors: Catherine L. Farrell, Francis H. Martin, Rachel Yabkowitz
  • Formulations for non-viral in vivo transfection in the lungs
    Patent number: 6022737
    Abstract: Formulations useful in improving non-viral in vivo transfection of DNA in the lungs are provided. Formulations which comprise DNA with various additives are prepared and delivered to the lungs resulting in production of a transcription product.
    Type: Grant
    Filed: November 2, 1995
    Date of Patent: February 8, 2000
    Assignee: Amgen Inc.
    Inventors: Ralph Niven, Daniel J. Freeman
  • Biodegradable microparticles for the sustained delivery of therapeutic drugs
    Patent number: 6020004
    Abstract: The present invention relates to improved methods of making polymeric microparticles containing a variety of active ingredients, e.g. protein drugs. In addition, the present invention relates to using the above active protein containing polymeric microparticles to prepare compositions for the sustained delivery of the therapeutics.
    Type: Grant
    Filed: April 17, 1997
    Date of Patent: February 1, 2000
    Assignee: Amgen Inc.
    Inventor: Subodh Shah
  • Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
    Patent number: 6017876
    Abstract: The present invention broadly relates to chemical modification of biologically active proteins or analogs thereof. More specifically, the present invention describes novel methods for site-specific chemical modification of various proteins, and resultant compositions having improved biocompatibility and bioactivity.
    Type: Grant
    Filed: July 21, 1998
    Date of Patent: January 25, 2000
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Olaf Kinstler
  • Use of NDF peptide as growth factor for sensory epithelium
    Patent number: 6017886
    Abstract: A non-naturally occurring peptide derived from EGF-like domains of NDF/heregulin protein isoforms is used to stimulate the proliferation of cells in the sensory epithelium of the inner ear.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: January 25, 2000
    Assignee: Amgen Inc.
    Inventor: Josette F. Carnahan
  • Implantable device containing GDNF secreting cells for treating nerve damage and methods of use
    Patent number: 6015572
    Abstract: A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process. An implantable device containing recombinant GDNF secreting cells encapsulated in a semipermeable membrane may be used to treat nerve damage in patients suffering from disorders such as Parkinson's disease.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: January 18, 2000
    Assignee: Amgen Inc.
    Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
  • Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
    Patent number: 6013253
    Abstract: The present invention encompasses methods for preventing and treating multiple sclerosis by administering to patients in need thereof a therapeutically effective amount of IFN-con in combination with IL-1ra.
    Type: Grant
    Filed: August 15, 1997
    Date of Patent: January 11, 2000
    Assignee: Amgen, Inc.
    Inventors: David Martin, Norman L. Fischer
  • Method for purifying keratinocyte growth factors
    Patent number: 6008328
    Abstract: The present invention concerns the purification of keratinocyte growth factors.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 28, 1999
    Assignee: Amgen Inc.
    Inventors: Eric W. Hsu, William C. Kenney, Tim Tressel
  • Polynucleotides encoding hepatocyte-specific members of the FGF family
    Patent number: 5998170
    Abstract: Nucleic acid molecules are described which are useful in vectors, transformed or transfected host cells, and methods for the recombinant expression of hepatocyte growth-specific polypeptide members of the FGF family.
    Type: Grant
    Filed: October 3, 1997
    Date of Patent: December 7, 1999
    Assignee: Amgen Inc.
    Inventors: Tsutomu Arakawa, Dimitry Michael Danilenko, Nobuyuki Itoh, Francis Hall Martin
  • N-terminally chemically modified protein compositions and methods
    Patent number: 5985265
    Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.
    Type: Grant
    Filed: June 20, 1997
    Date of Patent: November 16, 1999
    Assignee: Amgen Inc.
    Inventors: Olaf B. Kinstler, Nancy E. Gabriel, Christine E. Farrar, Randolph B. DePrince
  • Nucleic acids encoding EPH-like receptor protein tyrosine kinases
    Patent number: 5981246
    Abstract: Four novel members of the EPH sub-family of receptor protein tyrosine kinases are disclosed. Nucleic acid sequences encoding receptor proteins, recombinant plasmids and host cells for expression, and methods of producing and using such receptors are also disclosed.
    Type: Grant
    Filed: August 21, 1996
    Date of Patent: November 9, 1999
    Assignee: Amgen Inc.
    Inventors: Gary M. Fox, Andrew A. Welcher, Shuqian Jing